Molecular mechanism of dysfunctional factor VII associated with the homozygous missense mutation 33 I Gly to Ser

Thrombosis and Haemostasis

Volumn 93, Issue 3, 2005, Pages 414-419

  Takamiya, Osamu ^a   Kimura, Shinya ^b  

^a SHINSHU UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

Catalytic domain; Chromogenic substrate; Dysfunctional factor VII variant; Substrate binding region

Indexed keywords

BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 9; COMPLEMENTARY DNA; GLYCINE; MUTANT PROTEIN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; SERINE; THROMBOPLASTIN;

ADULT; AMINO ACID SUBSTITUTION; ARTICLE; BLOOD CLOTTING FACTOR 7 DEFICIENCY; CASE REPORT; CATALYSIS; ENZYME ACTIVITY; FEMALE; HAPLOTYPE; HOMOZYGOSITY; HUMAN; JAPAN; MACROMOLECULE; MISSENSE MUTATION; MOLECULAR DYNAMICS; MOLECULAR MODEL; MOLECULAR RECOGNITION; MOLECULAR WEIGHT; MUTATIONAL ANALYSIS; POLYACRYLAMIDE GEL ELECTROPHORESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN PURIFICATION; SEQUENCE ALIGNMENT; SINGLE STRAND CONFORMATION POLYMORPHISM; WILD TYPE;

CLONING, MOLECULAR; FACTOR VII; FACTOR VII DEFICIENCY; HOMOZYGOTE; HUMANS; MODELS, MOLECULAR; MUTATION, MISSENSE; PROTEIN BINDING; PROTEIN CONFORMATION;

EID: 15344338660     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH04-09-0632     Document Type: Article

References (29)

1. Bajaj SP, Rapaport SI, Brown SF. Isolation and characterization of human factor VII. Activation of factor VII by factor Xa. J Biol Chem 1981; 256: 253-9.
2. Masys DR, Bajaj SP, Rapaport SI. Activation of human factor VII by activated factors IX and X. Blood 1982; 60: 1143-50.
3. Kisiel W, Fujikawa K, Davie EW. Activation of bovine factor VII (proconvertin) by factor XIIa (activated Hageman factor). Biochemistry 1977; 16: 4189-94.
4. Nakagaki T, Foster DC, Berkner KL et al. Initiation of the extrinsic pathway of blood coagulation: Evidence for the tissue factor dependent autoactivation of human coagulation factor VII. Biochemistry 1991; 30: 10819-24.
5. Wildgoose P, Kisiel W. Activation of human factor VII by factors IXa and Xa on human bladder carcinoma cells. Blood 1989; 73: 1888-95.
6. O'Hara PJ, Grant FJ, Haldeman BA, et al. Nucleotide sequence of the gene coding for human factor VII, a vitamin K-dependent protein participating in blood coagulation. Proc Natl Acad Sci USA 1987; 84: 5158-62.
7. Triplett DA, Brandt JT, Batard MA, et al. Hereditary factor VII deficiency: heterogeneity defined by combined functional and immunochemical analysis. Blood 1985; 66: 1284-7.
8. Tuddenham EG, Pemberton S, Cooper DN. Inherited factor VII deficiency: genetics and molecular pathology. Thromb Haemost 1995; 74: 313-21.
9. Kunkel LM, Smith KD, Boyer SH, et al. Analysis of human Y-chromosome-specific reiterated DNA in chromosome variants. Proc Natl Acad Sci U S A 1977; 74: 1245-9.
10. Takamiya O. Assay of factor VII antigen by enzyme-linked immunosorbent assay (ELISA). Rinshobyori (Japanese) 1991; 39: 437-41.
11. Takamiya O, Okimoto Y. Severe factor VII deficiency with recurrent intracranial haemorrhages owing to double heterozygosity for a splice site mutation of an IVS4 and a novel nonsense mutation in exon 8 (Gln211->Term). Br J Haematol 2001; 114: 369-74.
12. Takamiya O, Yoshioka A. Factor VII binding to tissue factor in plasma from warfarin-treated individuals. Thromb Res 1996; 81: 657-63.
13. Takamiya O, Kemball-Cook G, Martin DM, et al. Detection of missense mutations by single-strand conformational polymorphism (SSCP) analysis in five dysfunctional variants of coagulation factor VII. Hum Mol Genet 1993; 2: 1355-9.
14. Takamiya O, Seta M, Tanaka K, et al. Human factor VII deficiency caused by S339C mutation located adjacent to the specificity pocket of the catalytic domain. Clin Lab Haematol 2002; 24: 233-8.
15. Orita M, Suzuki Y, Sekiya T, et al. Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics 1989; 5: 874-9
16. Humphries S, Temple A, Lane A, et al. Low plasma levels of factor VIIc and antigen are more strongly associated with the 10 base pair promoter (-323) insertion than the glutamine 353 variant. Thromb Haemost 1996; 75: 567-72.
17. van't Hooft FM, Silveira A, Tornvall P, et al. Two common functional polymorphisms in the promoter region of the coagulation factor VII gene determining plasma factor VII activity and mass concentration. Blood 1999; 93: 3432-4.
18. Chaing SH, Wallmark A, Berntorp E, et al. A Nla III polymorphism within the human factor VII gene. Hum Genet 1994; 93: 722-3.
19. Marchetti G, Gemmati D, Patracchini P, et al. PCR detection of a repeat polymorphism within the F7 gene. Nucleic Acids Res 1991; 19: 4570.
20. Green F, Kelleher C, Wilkes H, et al. A common genetic polymorphism associated with lower coagulation factor VII levels in healthy individuals. Arterioscler Thromb 1991; 11: 540-6.
21. Takamiya O, Hino K. A patient homozygous for a Gly354Cys mutation in factor VII that results in severely impaired secretion of the molecule, but not complete deficiency. Br J Haematol 2004; 124: 336-42.
22. Millar DS, Kemball-Cook G, McVey JH, et al. Molecular analysis of the genotype-phenotype relationship in factor VII deficiency. Hum Genet 2000; 107: 327-42.
23. Etro D, Pinotti M, Wulff K, et al. The Gly331Ser mutation in factor VII in Europe and the Middle East. Haematologica 2003; 88: 1434-6.
24. Pinotti M, Etro D, Bindini D, et al. Residual factor VII activity and different hemorrhagic phenotypes in CRM(+) factor VII deficiencies (Gly331Ser and Gly283Ser). Blood 2002; 99: 1495-7.
25. Zheng DQ, Shurafa M, James HL. Factor VII G331D: a variant molecule involving replacement of a residue in the substrate-binding region of the catalytic domain. Blood Coagul Fibrinolysis 1996; 7: 93-6
26. Banner DW, D'Arcy A, Chene C, et al. The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor. Nature 1996; 7; 380: 41-6.
27. Davidson CJ, Hirt RP, Lal K, et al. Molecular evolution of the vertebrate blood coagulation network. Thromb Haemost 2003; 89: 420-8.
28. Miyata T, Kojima T, Suzuki K, et al. Factor X Nagoya 1 and Nagoya 2: a CRM- factor X deficiency and a dysfunctional CRM+ factor X deficiency characterized by substitution of Arg306 by Cys and of Gly366 by Ser, respectively. Thromb Haemost 1998; 79: 486-90.
29. Liu JZ, Li X, Drost J, Thorland EC, et al. The human factor IX gene as germline mutagen test: Samples from mainland China have the putatively endogenous patter of mutation. Hum Mutat 2000; 16: 31-6.